Physician profile
Samuel Rivera
NPI 1235334400
$3,823.63
in general payments reported to CMS, 2019-2025
11 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $326 · 2021: $590 · 2022: $573 · 2023: $672 · 2024: $687 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $995.17 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $835.84 | 2020-2025 | Rinvoq, Mavyret |
| E.R. Squibb & Sons, L.L.C. | $777.31 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $357.50 | 2020-2025 | Entyvio |
| Pbg Puerto Rico LLC | $280.25 | 2019-2025 | |
| Janssen Biotech, INC. | $202.34 | 2020-2024 | Tremfya, Stelara |
| Olympus Latin America, INC. | $146.86 | 2025 | Evis Exera II Ultrasound Gastrovideoscope |
| Boston Scientific Corporation | $98.79 | 2019 | |
| Abbott Laboratories | $82.74 | 2025 | Proclaim |
| Pfizer Pharmaceuticals LLC | $34.03 | 2019 | |
| Gilead Sciences, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.